Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Naughton, M. A.
Right arrow Articles by Botto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naughton, M. A.
Right arrow Articles by Botto, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology, Vol 38, 640-644, Copyright © 1999 by British Society for Rheumatology

ORIGINAL PAPERS

Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine

MA Naughton, E Battaglia, S O'Brien, MJ Walport and M Botto
Imperial College of Science and Medicine, Rheumatology Section, London, UK.

OBJECTIVE: To determine whether the presence of polymorphisms associated with reduced or absent activity of thiopurine methyltransferase (TPMT), an enzyme involved in azathioprine metabolism, can predict side-effects, particularly myelosuppression, in patients taking this drug. METHODS: The TPMT genotype was determined in 120 patients with systemic lupus erythematosus (SLE) together with 15 patients with inflammatory bowel disease (IBD) and correlated with the effects of clinical exposure to azathioprine. RESULTS: TPMT polymorphisms were detected in eight patients. Severe marrow toxicity occurred in the single homozygote identified. Azathioprine was generally well tolerated, but 11 drug-associated neutropenias were detected. In only one of the 11 cases was a TPMT polymorphism identified. CONCLUSION: Homozygous TPMT deficiency was associated with severe marrow suppression. In the majority of cases, however, TPMT genotyping prior to azathioprine therapy would not have predicted myelosuppressive events and may augment, but not replace, regular blood monitoring.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 DTBHome page
TPMT testing before azathioprine therapy?
DTB, January 1, 2009; 47(1): 9 - 12.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
U. Boonsrirat, S. Angsuthum, S. Vannaprasaht, J. Kongpunvijit, N. Hirankarn, W. Tassaneeyakul, and Y. Avihingsanon
Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism
Lupus, February 1, 2008; 17(2): 132 - 134.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. P. R. Clunie and L. Lennard
Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine
Rheumatology, January 1, 2004; 43(1): 13 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
H. Corominas, M. Domenech, A. Laiz, I. Gich, C. Geli, C. Diaz, F. de Cuevillas, M. Moreno, G. Vazquez, and M. Baiget
Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients?
Rheumatology, January 1, 2003; 42(1): 40 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C. Siva, W. M. Yokoyama, and H. L. McLeod
Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field
Rheumatology, November 1, 2002; 41(11): 1273 - 1279.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
Y Ioannou and D A Isenberg
Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge
Postgrad. Med. J., October 1, 2002; 78(924): 599 - 606.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
L Lennard
TPMT in the treatment of Crohn's disease with azathioprine
Gut, August 1, 2002; 51(2): 143 - 146.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.